Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Abstract Background Results of conventional induction chemotherapies in primary central nervous system lymphoma (PCNSL) need to be improved. Ibrutinib, a BTK inhibitor, and lenalidomide, an immunomodulatory drug, have shown promising results at relapse, supporting to further assess their individual...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Marion Alcantara, Marion Chevrier, Fabrice Jardin, Anna Schmitt, Caroline Houillier, Lucie Oberic, Olivier Chinot, Franck Morschhauser, Frédéric Peyrade, Roch Houot, Khê Hoang-Xuan, Hervé Ghesquieres, Carole Soussain
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-09-01
coleção:	Journal of Hematology & Oncology
Assuntos:	Primary central nervous system lymphoma Phase IB trial Ibrutinib Lenalidomide
Acesso em linha:	https://doi.org/10.1186/s13045-024-01606-w
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!